Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xencor, Inc. - Common Stock (NQ:XNCR)

14.13 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Xencor, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
From Xencor, Inc.
Via Business Wire
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
From Xencor, Inc.
Via Business Wire
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Xencor, Inc.
Via Business Wire
Xencor to Participate at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Xencor Reports Second Quarter 2025 Financial Results
From Xencor, Inc.
Via Business Wire
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
From Xencor, Inc.
Via Business Wire
Xencor Reports First Quarter 2025 Financial Results
From Xencor, Inc.
Via Business Wire
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
From Xencor, Inc.
Via Business Wire
Xencor Appoints Todd Simpson to Board of Directors
From Xencor, Inc.
Via Business Wire
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
From Xencor, Inc.
Via Business Wire
Xencor to Participate at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Xencor Reports Third Quarter 2024 Financial Results
From Xencor, Inc.
Via Business Wire
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
From Xencor, Inc.
Via Business Wire
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
From Xencor, Inc.
Via Business Wire
Xencor Announces Upcoming Change to Board of Directors
From Xencor, Inc.
Via Business Wire
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Xencor, Inc.
Via Business Wire
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
From Xencor, Inc.
Via Business Wire
Xencor Announces Proposed Public Offering of Common Stock
From Xencor, Inc.
Via Business Wire
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
From Xencor, Inc.
Via Business Wire
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
From Xencor, Inc.
Via Business Wire
Xencor Reports Second Quarter 2024 Financial Results
From Xencor, Inc.
Via Business Wire
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
From Xencor, Inc.
Via Business Wire
Xencor Reports First Quarter 2024 Financial Results
From Xencor, Inc.
Via Business Wire
Xencor Appoints Bart Cornelissen as Chief Financial Officer
From Xencor, Inc.
Via Business Wire
Xencor to Present at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
From Xencor, Inc.
Via Business Wire
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
From Xencor, Inc.
Via Business Wire
Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Xencor, Inc.
Via Business Wire
Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy
From Xencor, Inc.
Via Business Wire
Xencor Reports Third Quarter 2023 Financial Results
From Xencor, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.